



First published on February 8, 2005, doi:10.1177/0363546504268135  
This version was published on April 1, 2005

*The American Journal of Sports Medicine* 33:515-523 (2005)  
© 2005 [American Orthopaedic Society for Sports Medicine](#)

## A Randomized, Double-Blind, Placebo-Controlled Study

Bernard Mazières, MD<sup>\*,†</sup>, Stéphanie Rouanet, DESS<sup>‡</sup>, Joanne Velicy, PhD<sup>‡</sup>, Claudia Scarsi, Pharm<sup>§</sup> and  
Valentina Reiner, PharB<sup>§</sup>

From the <sup>†</sup>Department of Rheumatology, Ranguel University Hospital, Toulouse, France, <sup>‡</sup>Therapharm Recherches, Boulogne-Billancourt, France, and <sup>§</sup>Applied Pharma Research S.A., Balerna, Switzerland

\*Nonsteroidal anti-inflammatory drugs (NSAIDs) have proved to be effective in the treatment of soft tissue injuries such as sprains, strains, and contusions.<sup>10,13,15,20,22</sup> Oral NSAIDs are often adjuncts to treatment but can cause serious systemic side effects. Applied topically, these drugs are formulated to penetrate the skin, subcutaneous fatty tissue, and muscle in amounts sufficient to exert therapeutic effects, while plasma levels remain low.<sup>24,30</sup> Topical NSAIDs offer the advantage of local, enhanced drug delivery to affected tissues with a reduced incidence of systemic adverse events (AEs), such as peptic ulcer disease and gastrointestinal hemorrhage.<sup>16</sup>